Cardiovascular drug therapy in the elderly
著者
書誌事項
Cardiovascular drug therapy in the elderly
(Developments in cardiovascular medicine, v. 72)
Nijhoff Pub. , Distributors for the U.S. and Canada, Kluwer Academic Publishers, c1988
大学図書館所蔵 全2件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes index
内容説明・目次
内容説明
Cardiovascular drug therapy has markedly progressed in the recent decades. Not only have new drugs been introduced to clinical practice, but new classes of drugs have been developed. While in 1960 the practicing cardiolo gist had a selection of about only ten drugs, in 1987 about 150 drugs are routinely used in cardiovascular diseases. Elderly patients, however, usually do not enjoy the full benefit of this progress. This might be due to lack of knowledge, a conservative approach, or the worldwide tendency not to try new drugs in the elderly. It is now clear that the majority of patients that will be treated in car diovascular clinics will be, in the near future, elderly patients. Even now, elderly patients form about one-third of the patients with cardiovascular diseases. These patients are approached, however, according to criteria devel oped for younger populations. This is despite the fact that elderly patients differ from younger ones in most aspects, including pathology, epidemiol ogy, pathophysiology, diagnostic approach, management, pharmacology, pharmacokinetics, rehabilitation, and supportive treatment. It is the purpose of this book to present to the clinician all drugs with which there is clinical experience in the elderly or which might be potentially useful for the elderly with cardiovascular diseases. The data are presented without the authors taking a position. This should allow the clinicians to make their own selection and individualize treatment, vii viii Preface based on a wide data base. Comparative data are presented only when specific comparative studies were performed.
目次
I. Agents Directly Enhancing Myocardial Contractility.- 1. Introduction.- 2. Digitalis glycosides.- 3. Bipyridine derivatives.- 4. Dobutamine.- 5. Dopamine.- 6. MDL-17,043 (Piroximone).- 7. Ibopamine.- II. Vasodilators.- 8. Introduction.- 9. Captopril.- 10. Enalapril.- 11. Enalaprilat.- 12. Nifedipine.- 13. Nitrendipine.- 14. Verapamil.- 15. Diltiazem.- 16. Prazosin.- 17. Urapidil.- 18. Nitrates.- 19. Nitroprusside.- 20. Hydralazine.- 21. Endralazine.- 22. Minoxidil.- III. Antiarrhythmic Drugs.- 23. Introduction.- 24. Quinidine.- 25. Disopyramide.- 26. Lidocaine.- 27. Tocainide.- 28. Lorcainide.- 29. Propafenone.- 30. Mexiletine.- 31. Ethmozine.- 32. Encainide.- 33. Amiodarone.- 34. Adenosine.- IV. Beta-Adrenoreceptor Blockers.- 35. Introduction.- 36. Propranolol.- 37. Atenolol.- 38. Metoprolol.- 39. Oxprenolol.- 40. Alprenolol.- 41. Sotalol.- 42. Esmolol.- V. Centrally Acting Antihypertensive Agents.- 43. Introduction.- 44. Methyldopa.
「Nielsen BookData」 より